Invivyd Reports Third Quarter 2026 Financial Results and Recent

Invivyd, Inc. (IVVD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Invivyd Reports Third Quarter 2026 Financial Results and Recent Business Highlights • DECLARATION Phase 3 clinical trial data on VYD2311 (ibramvibart) to be available imminently, per the Accelerated Approval analysis and regulatory submission plan previously communic

Event · Earnings
Original reporting
Published Nov 16, 2026, 12:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$IVVD
Bullish
high confidence
Mentioned
$IVVD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$IVVDBullishHigh
01

Why it matters

The filing provides the first public confirmation of pivotal trial success, a catalyst for price movement.

02

Market read

First‑report of trial data and earnings; likely to drive short‑term stock reaction.

03

What to watch

Potential regulatory delays or competition from other COVID‑19 therapies could temper upside.

Relevance 7/10Novelty 9/10Timing: today

Background

Invivyd filed a Form 8‑K reporting Q3 2026 results, product revenue growth, and positive Phase 3 data for its VYD2311 antibody.

Company-level read

Ticker impact

$IVVDBullishHigh confidence
Context

Q3 2026 financial results and positive Phase 3 trial data for VYD2311 disclosed in an 8‑K filing.

Expected impact

likely upside as investors price in the favorable Phase 3 data and revenue growth

Evidence & confidence

First public disclosure of pivotal trial results and revenue increase; biotech stocks typically react strongly to such news.

Market effects

Strengthens confidence in monoclonal‑antibody COVID therapeutics, may benefit peer biotech firms.

U.S. biotech sector could see modest gains on the day.

Limited to biotech investors; no broad market effect.

Counterpoint

If the interim data are not as robust as presented, the stock could face a pull‑back.

Key entities

  • Invivyd, Inc.

    Biotech firm developing monoclonal antibodies for COVID‑19 and measles.

  • Marc W. Elia

    Appointed Chairman and CEO of Invivyd.

Related articles

$IVVDMed

Invivyd Posts Wider Loss In Q3 As Operating Expenses Rise

Invivyd, Inc. (IVVD) reported a wider Q3 net loss of $33.47 million, up from $10.47 million YoY, due to higher operating expenses. Revenue rose 18% to $15.45 million. The company provided updates on its pipeline, including VYD2311 for COVID-19 and VMS063 for measles, and announced leadership changes. Cash reserves totaled $126.40 million.

$IVVDMedAI 8/10

Invivyd presents preclinical data on measles antibody candidate

Invivyd (NASDAQ:IVVD) presented preclinical data for its measles antibody candidate VMS063 at IDWeek 2026, showing antiviral activity against measles virus variants. The company plans to scale up manufacturing for clinical development in 2027. There are currently no FDA-approved treatments for measles, with U.S. cases nearly double in 2026 compared to 2025, according to Invivyd.

$IVVDLow

Invivyd, Inc. (IVVD) Unveils Preclinical Data for Measles mAb VMS063

Invivyd, Inc. (IVVD) presented preclinical data for VMS063, a novel monoclonal antibody for measles, showing in vitro activity against contemporary virus variants. The company is scaling up production for clinical development in 2027. There are currently no FDA-approved treatments for measles, and the U.S. is experiencing a surge in cases.

$IVVDLowAI 8/10

More than 9 million U.S. children are estimated to lack measles protection. Lab tests found an antibody could fight measles.

Invivyd (Nasdaq: IVVD) presented preclinical data for VMS063, a monoclonal antibody candidate for measles treatment and prevention. VMS063 showed potent in vitro activity against measles virus variants. Invivyd plans to scale up production for clinical development in 2027. The U.S. is experiencing a record number of measles cases in 2026, with over 9 million children unprotected.

$IVVDMedAI 8/10

Invivyd launches phase 2 trial of VYD2311 for long COVID

Invivyd (NASDAQ:IVVD) initiated a Phase 2 trial of VYD2311 for Long COVID and Post-Vaccination Syndrome. The trial will enroll 130 participants and assess safety, tolerability, and efficacy over 90 days. VYD2311 has shown in vitro potency against SARS-CoV-2 variants. Initial data is expected in mid-2027. The trial is part of Invivyd’s broader REVOLUTION clinical program.